Valsts: Nīderlande
Valoda: holandiešu
Klimata pārmaiņas: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
BICALUTAMIDE 50 mg/stuk
Bennett Pharmaceuticals S.A 20 Agias Kiriakis street 14561 ATHENE (GRIEKENLAND)
L02BB03
BICALUTAMIDE 50 mg/stuk
Filmomhulde tablet
HYPROMELLOSE (E 464) ; LACTOSE 1-WATER ; MACROGOLEN ; MAGNESIUMSTEARAAT (E 470b) ; NATRIUMLAURILSULFAAT ; NATRIUMZETMEELGLYCOLAAT ; POLYDEXTROSE (E 1200) ; POVIDON (E 1201) ; SILICIUMDIOXIDE (E 551) ; TITAANDIOXIDE (E 171) ; TRIETHYLCITRAAT (E 1505), HYPROMELLOSE (E 464) ; LACTOSE 1-WATER ; MACROGOLEN ; MAGNESIUMSTEARAAT (E 470b) ; NATRIUMLAURILSULFAAT (E 487) ; NATRIUMZETMEELGLYCOLAAT ; POLYDEXTROSE (E 1200) ; POVIDON (E 1201) ; SILICIUMDIOXIDE (E 551) ; TITAANDIOXIDE (E 171) ; TRIETHYLCITRAAT (E 1505), HYPROMELLOSE (E 464) ; LACTOSE 1-WATER ; MACROGOLEN ; MAGNESIUMSTEARAAT (E 470b) ; NATRIUMLAURILSULFAAT (E 487) ; NATRIUMZETMEELGLYCOLAAT (E468) ; POLYDEXTROSE (E 1200) ; POVIDON (E 1201) ; SILICIUMDIOXIDE (E 551) ; TITAANDIOXIDE (E 171) ; TRIETHYLCITRAAT (E 1505),
Oraal gebruik
Bicalutamide
Hulpstoffen: HYPROMELLOSE (E 464); LACTOSE 1-WATER; MACROGOLEN; MAGNESIUMSTEARAAT (E 470b); NATRIUMLAURILSULFAAT (E 487); NATRIUMZETMEELGLYCOLAAT (E468); POLYDEXTROSE (E 1200); POVIDON (E 1201); SILICIUMDIOXIDE (E 551); TITAANDIOXIDE (E 171); TRIETHYLCITRAAT (E 1505);
1900-01-01
PACKAGE LEAFLET: INFORMATION FOR THE USER BILUMIDE 50 MG, FILMOMHULDE TABLETTEN Bicalutamide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IM- PORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Bilumide 50 mg, FILMOMHULDE TABLETTEN is and what it is used for 2. What you need to know before you take Bilumide 50 mg, FILMOMHULDE TABLETTEN 3. How to take Bilumide 50 mg, FILMOMHULDE TABLETTEN 4. Possible side effects 5. How to store Bilumide 50 mg, FILMOMHULDE TABLETTEN 6. Contents of the pack and other information 1. WHAT BILUMIDE 50 MG, FILMOMHULDE TABLETTEN IS AND WHAT IT IS USED FOR Bilumide 50 mg, FILMOMHULDE TABLETTEN is one of a group of drugs called anti-androgens. It interferes with some of the actions of the male sex hormones. Bilumide 50 mg used to treat prostate cancer. It is used as combination therapy in tumor stages called ‘advanced’ together with other treatments such as surgical castration or drugs which reduce the levels of androgens in the body. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE BILUMIDE 50 MG, FILMOMHULDE TABLETTEN DO NOT TAKE BILUMIDE 50 MG, FILMOMHULDE TABLETTEN - if you are allergic to bicalutamide or any of the other ingredients of this medicine (listed in sec- tion 6). - if you are a woman, a child or an adolescent. - if you are taking any medications containing terfenadine, astemizole or cisapride (see ‘Other medi- cines and Bilumide 50 mg, filmomhulde tabletten’, below. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Bilumide 50 mg: - if you have any liver problems. Bicalutamide level Izlasiet visu dokumentu
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Bilumide 50 mg, filmomhulde tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains 50 mg bicalutamide. Excipient with known effect: lactose monohydrate 58.56 mg. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM White film coated tablet, debossed with "BIC 50" on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of advanced prostate cancer in combination with LHRH analogue therapy or surgical castration. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adult males including the elderly: one tablet (50 mg) daily with or without food. Treatment with bicalutamide should be commenced at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration. _Paediatric population_ Bicalutamide is not indicated in children. Patients with renal impairment: No dosage adjustment is necessary in patients with renal im- pairment. Patients with hepatic impairment: No dosage adjustment is necessary in patients with mild he- patic impairment. Increased accumulation may occur in patients with moderate to severe hepatic impairment (see section 4.4 ). 4.3 CONTRAINDICATIONS Bicalutamide is contra-indicated in females and children (see section 4.6). Bicalutamide must not be given to any patient who has shown a hypersensitivity reaction to the active substance or to any of the excipients listed in section 6.1. Co-administration of terfenadine, astemizole or cisapride with bicalutamide is contraindicated (see section 4.5). 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Initiation of treatment should be under the direct supervision of a specialist. Bicalutamide is extensively metabolised in the liver. Data suggests that its elimination may be slower in subjects with severe hepatic impairment and this could lead to increased accumulation of bicalutamide. Therefore, bicalutamide should be used with caution in patients with moderate to severe hepatic impairment. Periodic Izlasiet visu dokumentu